Evidence map›Paper›PMID 33462955›Full record

Trial reportDiabetes, obesity & metabolism2020

The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes.

Jonathan M Wilson, Amir Nikooienejad, Deborah A Robins, William C Roell, Jeffrey S Riesmeyer, Axel Haupt, Kevin L Duffin, Marja-Riitta Taskinen, Giacomo Ruotolo

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes, obesity & metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 4 pooled it
11.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 4 syntheses or guidelines pooled it, 151 citations in OpenAlex.

  1. Pooled it
  2. Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus and Cardiovascular Disease: The Past, Present, and Future.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2022
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Review
  13. Biologics for cardiovascular diseases: from bench to bedside.Signal transduction and targeted therapy · 2026
    Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Jonathan M WilsonEli Lilly and Company, Indianapolis, Indiana, USA.
Amir NikooienejadEli Lilly and Company, Indianapolis, Indiana, USA.
Deborah A RobinsEli Lilly and Company, Indianapolis, Indiana, USA.ORCID 0000-0001-9694-7319
William C RoellEli Lilly and Company, Indianapolis, Indiana, USA.
Jeffrey S RiesmeyerEli Lilly and Company, Indianapolis, Indiana, USA.
Axel HauptEli Lilly and Company, Indianapolis, Indiana, USA.ORCID 0000-0003-4502-0470
Kevin L DuffinEli Lilly and Company, Indianapolis, Indiana, USA.
Marja-Riitta TaskinenResearch Program for Clinical and Molecular Medicine Unit, Diabetes and Obesity, University of Helsinki, Helsinki, Finland.
Giacomo RuotoloEli Lilly and Company, Indianapolis, Indiana, USA.ORCID 0000-0001-5247-5444
Eli Lilly (United States) · USUniversity of Helsinki · FI

Funding

This study was funded by Eli Lilly and Company.
6 · The paper itself

Abstract

aimTo better understand the marked decrease in serum triglycerides observed with tirzepatide in patients with type 2 diabetes, additional lipoprotein-related biomarkers were measured post hoc in available samples from the same study. MATERIALS AND

methodsPatients were randomized to receive once-weekly subcutaneous tirzepatide (1, 5, 10 or 15 mg), dulaglutide (1.5 mg) or placebo. Serum lipoprotein profile, apolipoprotein (apo) A-I, B and C-III and preheparin lipoprotein lipase (LPL) were measured at baseline and at 4, 12 and 26 weeks. Lipoprotein particle profile by nuclear magnetic resonance was assessed at baseline and 26 weeks. The lipoprotein insulin resistance (LPIR) score was calculated.

resultsAt 26 weeks, tirzepatide dose-dependently decreased apoB and apoC-III levels, and increased serum preheparin LPL compared with placebo. Tirzepatide 10 and 15 mg decreased large triglyceride-rich lipoprotein particles (TRLP), small low-density lipoprotein particles (LDLP) and LPIR score compared with both placebo and dulaglutide. Treatment with dulaglutide also reduced apoB and apoC-III levels but had no effect on either serum LPL or large TRLP, small LDLP and LPIR score. The number of total LDLP was also decreased with tirzepatide 10 and 15 mg compared with placebo. A greater reduction in apoC-III with tirzepatide was observed in patients with high compared with normal baseline triglycerides. At 26 weeks, change in apoC-III, but not body weight, was the best predictor of changes in triglycerides with tirzepatide, explaining up to 22.9% of their variability.

conclusionsTirzepatide treatment dose-dependently decreased levels of apoC-III and apoB and the number of large TRLP and small LDLP, suggesting a net improvement in atherogenic lipoprotein profile.

Indexed as

Cardiovascular DiseasesDiabetes Mellitus, Type 2Insulin ResistanceBiomarkersGastric Inhibitory PolypeptideGlucagon-Like Peptide-1 ReceptorHeart Disease Risk FactorsHumansLipoproteinsRisk FactorsTirzepatideTriglyceridesBiomarkersGastric Inhibitory PolypeptideGlucagon-Like Peptide-1 ReceptorLipoproteinsTirzepatideTriglyceridesincretin therapy, type 2 diabetes

Identifiers

PMID33462955
PMCPMC7756479
OpenAlexW3049084794

What Socratic holds

Texttitle and abstract
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.